Sanofi Completes Acquisition of Dynavax, Expanding Adult Vaccination Presence.

Tuesday, Feb 10, 2026 9:02 am ET1min read
DVAX--
SNY--

Sanofi has completed the acquisition of Dynavax, a vaccine company, for $15.50 per share. The deal includes Dynavax's hepatitis B vaccine, HEPLISAV-B, and its candidate vaccine for shingles, Z-1018, as well as other vaccine projects in development. The acquisition expands Sanofi's presence in adult vaccinations and combines Dynavax's vaccines with Sanofi's commercial reach, global scale, and development capabilities.

Sanofi Completes Acquisition of Dynavax, Expanding Adult Vaccination Presence.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet